Bolt Biotherapeutics
Kristi Balacy is currently the Director Clinical Operations at Bolt Biotherapeutics, Inc. Kristi previously held the position of Director Clinical Operations at QED Therapeutics and Associate Director Clinical Operations at Corcept Therapeutics. With extensive experience in overseeing global clinical studies, Kristi has worked on various therapeutic areas such as skeletal dysplasia, Cushing syndrome, and lymphoma. Kristi has a background in Biology from UC Irvine and a M.A.S. in Clinical Research from UC San Diego. Kristi has also worked in roles such as Clinical Research Coordinator and Clinical Research Associate at various research institutes and pharmaceutical companies.
This person is not in any teams
Bolt Biotherapeutics
7 followers
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.